pharma · Dermatitis atopic · Cancer
Sanofi-Aventis U.S
Sanofi-aventis Healthcare Pty Ltd
Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater, USA
- Employees
- 177
- Programs
- 117
- Drugs
- 148
- Patents
- 0
DRI19220
Phase 2 · other · Hidradenitis suppurativa
DRI19220 for Hidradenitis suppurativa is a Phase 2 program (other) at Sanofi-aventis Healthcare Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code DRI19220
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi-aventis Healthcare Pty Ltd
- Phase
- Phase 2
- Modality
- other
- Indication
- Hidradenitis suppurativa
- Status
- active
- Trials
- 1